Recce Pharmaceuticals New Family 4 Patent to be granted

Recce Pharmaceuticals Limited (ASX: RCE) has received notification of intent to grant the first of Recce's new Patent Family 4 for RECCE's anti-infectives from the Australian Patent Office. The patent covers the process for the preparation of biologically active copolymers, including RECCE 327 and RECCE 529, and their use in treating bacterial and viral infections. The administration may be oral, inhalation, transdermal delivery, injection, aerosol, gel, topical foam or ointment.

The patent will expire in 2041, and with over 40 patents worldwide, the company’s monopolies for its new class of anti-infectives are valid until at least January 2041. Family 4 covers various bacterial pathogens, including Escherichia coli, Staphylococcus aureus, and Streptococcus pneumoniae, and viral pathogens such as HIV, cytomegalovirus, and Influenza A. SARS-CoV-2 is also covered in the patent.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com